There are two types of T-cells that operate within our immune systems: these are the effector T-cells (cancer killers) and regulatory T-cells (cancer enablers). We made this video for Cancer Research UK to describe exciting new research on an antibody (CD25nib) that signals drugs to kill regulatory T-cells, whilst ignoring effector T-cells. This pioneering approach essentially harnesses the immune system to kill cancer cells, through releasing the brakes on effector T-cells.
For more information:
Cancer Research UK - cancerresearchuk.org/
Cancer Research UK on CD25nib - news.cancerresearchuk.org/2021/04/12/how-uk-researchers-commercialised-cd25-as-an-immunotherapy-drug-target/
You can read the original research paper here - www.nature.com/articles/s4301...
14 ноя 2022
